<DOC>
	<DOCNO>NCT00740584</DOCNO>
	<brief_summary>To assess retention anti-viral activity ( human immunodeficiency virus ( HIV ) herpes simplex virus 2 ( genital herpes , HSV-2 ) SPL7013 cervicovaginal sample take 24 hour administration 3 % SPL7013 vagina . There hypothesis study .</brief_summary>
	<brief_title>Retention Duration Activity SPL7013 ( VivaGelÂ® ) After Vaginal Dosing .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<criteria>Healthy woman age 1845 regular menstrual cycle , free sexually transmitted infection use adequate contraception Any condition , include genital condition , sexually transmitted infection , menopause , and/or allergy would make study participant unsuitable study . Pregnancy breastfeed</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Prevention</keyword>
</DOC>